2025年5月23日,江苏恒瑞医药股份有限公司(以下简称恒瑞医药,600276.SH / 1276.HK)成功登陆港交所主板,实现“A+H”两地上市,募集资金达98.90亿港元,系2021年以来香港市场医疗健康行业最大规模IPO项目。中信证券在本次发行中担任联席账簿管理人及联席牵头经办人。“创新+国际化”双轮驱动创新药龙头企业开启“A+H”双平台时代恒瑞医药是一家根植中国、全球领先的创新型制药企业...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.